BrainsWay (BWAY) Stock Overview
Develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BWAY from our risk checks.
BWAY Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
BrainsWay Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪28.05 |
| 52 Week High | ₪29.40 |
| 52 Week Low | ₪14.44 |
| Beta | 0.27 |
| 1 Month Change | 7.93% |
| 3 Month Change | 6.49% |
| 1 Year Change | 49.76% |
| 3 Year Change | 795.31% |
| 5 Year Change | 172.86% |
| Change since IPO | 81.86% |
Recent News & Updates
Recent updates
Shareholders Will Probably Hold Off On Increasing BrainsWay Ltd.'s (TLV:BWAY) CEO Compensation For The Time Being
Sep 05
After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar
Aug 23Investors Will Want BrainsWay's (TLV:BWAY) Growth In ROCE To Persist
Jun 29After Leaping 25% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar
May 21After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar
Aug 23We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth
May 03BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce
Dec 25We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely
Dec 21We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely
Sep 19We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate
Jun 01We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth
Aug 15BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans
May 13BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business
Jan 31Shareholder Returns
| BWAY | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | -0.6% | -3.0% | 0.9% |
| 1Y | 49.8% | 29.8% | 41.9% |
Return vs Industry: BWAY exceeded the IL Medical Equipment industry which returned 29.8% over the past year.
Return vs Market: BWAY exceeded the IL Market which returned 41.9% over the past year.
Price Volatility
| BWAY volatility | |
|---|---|
| BWAY Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in IL Market | 7.5% |
| 10% least volatile stocks in IL Market | 3.3% |
Stable Share Price: BWAY has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: BWAY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 120 | Hadar Levy | www.brainsway.com |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.
BrainsWay Ltd. Fundamentals Summary
| BWAY fundamental statistics | |
|---|---|
| Market cap | ₪1.08b |
| Earnings (TTM) | ₪20.24m |
| Revenue (TTM) | ₪159.01m |
Is BWAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BWAY income statement (TTM) | |
|---|---|
| Revenue | US$49.09m |
| Cost of Revenue | US$12.32m |
| Gross Profit | US$36.78m |
| Other Expenses | US$30.53m |
| Earnings | US$6.25m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 74.92% |
| Net Profit Margin | 12.73% |
| Debt/Equity Ratio | 0% |
How did BWAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 20:41 |
| End of Day Share Price | 2025/12/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BrainsWay Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Carl Byrnes | Northland Capital Markets |